 Investors in the San Diego-based developer of diagnostic tests and equipment have seen their shares soar 149 since the start of 2020. While many companies have reduced or withdrawn 2020 financial guidance, GenMark increased its projected revenue twice, spurred by demand for its rapid test for COVID-19. Importantly, the management team highlighted on the first-quarter earnings conference call that suspected COVID-19 patients often get screened with GenMarks respiratory panel first. 